- Home
- VALN vs ANAB Comparison
VALN vs ANAB Comparison
Compare VALN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- ANAB
- Stock Information
- Founded
- VALN 2012
- ANAB 2005
- Country
- VALN France
- ANAB United States
- Employees
- VALN N/A
- ANAB N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- ANAB Health Care
- Exchange
- VALN Nasdaq
- ANAB Nasdaq
- Market Cap
- VALN 777.9M
- ANAB 659.6M
- IPO Year
- VALN 2021
- ANAB 2017
- Fundamental
- Price
- VALN $10.44
- ANAB $33.41
- Analyst Decision
- VALN Strong Buy
- ANAB Buy
- Analyst Count
- VALN 4
- ANAB 11
- Target Price
- VALN $15.75
- ANAB $53.67
- AVG Volume (30 Days)
- VALN 77.5K
- ANAB 651.0K
- Earning Date
- VALN 11-06-2025
- ANAB 11-04-2025
- Dividend Yield
- VALN N/A
- ANAB N/A
- EPS Growth
- VALN N/A
- ANAB N/A
- EPS
- VALN N/A
- ANAB N/A
- Revenue
- VALN $230,566,060.00
- ANAB $123,164,000.00
- Revenue This Year
- VALN $15.69
- ANAB $11.62
- Revenue Next Year
- VALN $22.15
- ANAB $15.31
- P/E Ratio
- VALN N/A
- ANAB N/A
- Revenue Growth
- VALN 25.47
- ANAB 304.17
- 52 Week Low
- VALN $3.62
- ANAB $12.21
- 52 Week High
- VALN $12.25
- ANAB $36.54
- Technical
- Relative Strength Index (RSI)
- VALN 51.09
- ANAB 72.35
- Support Level
- VALN $10.08
- ANAB $31.18
- Resistance Level
- VALN $11.35
- ANAB $33.97
- Average True Range (ATR)
- VALN 0.43
- ANAB 2.25
- MACD
- VALN -0.13
- ANAB 0.37
- Stochastic Oscillator
- VALN 29.25
- ANAB 92.68
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).